Royce & Associates’s Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 CANO.WS Stock Holding History

Royce & Associates’s Portfolio CANO.WS Stock Details CANO.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-49,999	Closed	-$10.5K	–	959
2023 Q2	$10.5K	Hold	49,999	–	–	﹤0.01%	912
2023 Q1	$8K	Hold	49,999	–	–	﹤0.01%	911
2022 Q4	$11K	Hold	49,999	–	–	﹤0.01%	906
2022 Q3	$132K	Hold	49,999	–	–	﹤0.01%	897
2022 Q2	$34K	Hold	49,999	–	–	﹤0.01%	933
2022 Q1	$79K	Hold	49,999	–	–	﹤0.01%	952
2021 Q4	$119K	Hold	49,999	–	–	﹤0.01%	956
2021 Q3	$206K	Hold	49,999	–	–	﹤0.01%	969
2021 Q2	$184K	Buy	+49,999	New	+$226K	﹤0.01%	993

Other funds holding CANO.WS

Zazove Associates Incline Village, Nevada $1.22B AUM 1.91% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Royce & Associates's CANO.WS Position: Q3 2023 in Review

Royce & Associates sold out of Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 (CANO.WS) in Q3 2023, closing a stake of 49,999 shares — an estimated $10.5K sold.

Royce & Associates first reported a position in CANO.WS in Q2 2021 and held it in 9 quarters. The position peaked at $206K in Q3 2021. 21 funds tracked by Wall St. Rank hold CANO.WS as of Q3 2023.

Royce & Associates reported no remaining Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 position as of Q3 2023 after selling out during the quarter.
Royce & Associates sold 49,999 Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 shares in Q3 2023, an estimated $10.5K.
Royce & Associates first reported a position in Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 in Q2 2021 and held it in 9 quarters.
Royce & Associates's Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 position peaked at $206K in Q3 2021.
21 funds tracked by Wall St. Rank held Cano Health, Inc. Redeemable Warrants, each whole warrant is exercisable for one-one hundredth (1/100th) of a share of Class A Common Stock at an exercise price of $1,150 as of Q3 2023.

Based on Royce & Associates's 13F filing for Q3 2023, filed 9 Nov 2023.